Not sure how quickly they can recover from missing the primaru endpoint."BELLUS Health shares are trading lower after the company's phase 2 trial of BLU-5937 for chronic cough missed its primary endpoint. "
Why do you think this is going to have a significant bounce back? Are you counting on their phase 2 trials? Meaning, past the current $3.99